01871nas a2200205   4500000000100000008004100001260001600042653004100058100001200099700001200111700001400123700001900137700001300156700001500169245011100184856015300295300001100448520119200459022001401651       2025                            d  bElsevier BV10aFemale genital schistosomiasis (FGS)1 aMberu M1 aZongo K1 aLeaning E1 aMakau-Barasa L1 aKamara K1 aJacobson J00aFemale Genital Schistosomiasis: Addressing Diagnostic and Programmatic Gaps to Advance Elimination Efforts  uhttps://www.sciencedirect.com/science/article/pii/S1201971225000220/pdfft?md5=c4590ff6bcdeca1f603ccd46a02f873c&pid=1-s2.0-S1201971225000220-main.pdf  a1077983 a<h2>Highlights</h2>

<ul>
	<li>
	<p>Gaps in knowledge, diagnostics, and program implementation of FGS</p>
	</li>
	<li>
	<p>Case studies on various approaches to address integration in addressing FGS</p>
	</li>
	<li>
	<p>Multi-sectoral partnerships that align health initiatives to FGS as morbidity</p>
	</li>
</ul>

<h2>Abstract</h2>

<p>This report underscores the critical need to include Female Genital Schistosomiasis (FGS) within schistosomiasis elimination frameworks and sexual and reproductive health programs. Affecting an estimated 40–56 million women, mainly in sub-Saharan Africa, FGS is often underdiagnosed and neglected in public health programs. This paper highlights FGS as a vital gap in schistosomiasis control and comprehensive sexual and reproductive health services, advocating for integrated approaches that address FGS awareness and diagnosis within disease elimination initiatives and health services. Enhanced diagnostic and treatment capabilities for FGS in endemic regions are essential to alleviate the physical, psychological, and reproductive health impacts on affected women and to advance global schistosomiasis elimination goals.</p>
  a1201-9712